Category Archives: Top Corporate News
CAPITALSTARS – भारत में खरीदारी के लिए बेहतर हैं ये स्टॉक: 23 APR 2019
Morning news and update The Nifty opened the session with a gap down and, as the day progressed, selling pressure intensified and Nifty ended the session below the crucial psychological mark of 11,600 with a loss of 1.35 per cent. The price action formed a long bear candle carrying lower high-low. Also, the opening price
TOP CORPORATE NEWS- 22 APR 2019
DHFL declines 10% after Crisil revises credit rating Shares of Dewan Housing Finance Corporation (DHFL) plunged 10% on Monday after rating agency CRISIL downgraded credit rating of the company’s commercial paper and continued on watch negative.Crisil downgraded commercial papers worth Rs850cr from to , with a rating watch of negative implications. The rating agency cited
CAPITALSTARS – भारत में खरीदारी के लिए बेहतर हैं ये स्टॉक: 22 APR 2019
Morning news and update The volatility increased at lifetime highs even as Nifty ended on a flat note. Reliance and auto stock rescued the market from closing below Tuesday low. The price action of the day formed a sizeable bearish candle and we observe formation of a dark cloud cover-like candlestick pattern. Interestingly, the open
TOP CORPORATE NEWS- 18 APR 2019
DCB Bank Q4FY19 PAT rises 50% Shares of DCB Bank gained 1% on Thursday after bank profit in the final quarter of FY19 rose 50% yoy to Rs96cr and NII for the same period under review grew 13.8% at Rs300.9cr.The bank operating profit stood at Rs185cr vs. Rs142cr for the same period as compared to
CAPITALSTARS – भारत में खरीदारी के लिए बेहतर हैं ये स्टॉक: 18 APR 2019
Morning news and update 18 April 2019 It was celebration time on the Dalal Street as the Nifty closed at a new record high and, on intra-day basis, it tested another milestone of 11,800. However, in the end, Nifty settled at 11,787, up by 97 points. The price action formed a sizeable bull candle which
TOP CORPORATE NEWS- 16 APR 2019
Lupin gets USFDA approval for Fluoxetine tablets USP Lupin in its filing to the exchanges on Tuesday informed that the company has received approval for its Fluoxetine Tablets USP, 10 mg and 20 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Company’s (Eli Lilly)
